November 10, 2020
Factor Bioscience Granted Second U.S. Patent for mRNA Vectorization of TALENs Technology
Factor Bioscience Inc., a Cambridge-based biotechnology company that develops cell-engineering technologies, today announced that the United States Patent and Trademark Office has granted Factor Bioscience U.S. Patent No. 10,829,738 covering methods for producing gene-edited cells using mRNA encoding transcription activator-like effector nucleases (TALENs). This patent is the second Factor has been granted for the mRNA vectorization of TALENs in 2020.
January 13, 2022
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
October 25, 2021
September 15, 2021